Search Results | Cancer Research | American Association for Cancer Research

1-20 of 66

2 3 4

Sort by

Sort Order Select

Journal Articles

Abstract 3939: Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy

Saijie Zhu, Douglas D. Fang, Qiang Li, Dongmei Yang, Shoulai Gu, Shaomeng Wang, Dajun Yang, Yifan Zhai

Cancer Res (2022) 82 (12_Supplement): 3939.

DOI: https://doi.org/10.1158/1538-7445.AM2022-3939

Published: 15 June 2022

View article

Journal Articles

Abstract 2664: Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors

Shaoulai Gu, Qiang Li, Chao Li, Qixin Wang, Douglas D. Fang, Shaomeng Wang, Dajun Yang, Yifan Zhai

Cancer Res (2022) 82 (12_Supplement): 2664.

DOI: https://doi.org/10.1158/1538-7445.AM2022-2664

Published: 15 June 2022

View article

Journal Articles

Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer

Yunful Deng, Guangzhi Ma, Karin A. Vallega, Dongsheng Wang, Mingliang Wang, Changwei Wang, Shaomeng Wang, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2022) 82 (12_Supplement): 428.

DOI: https://doi.org/10.1158/1538-7445.AM2022-428

Published: 15 June 2022

View article

Journal Articles

Abstract 1231: Identification of selective Brd4 degrader for cancer treatment

Biao Hu, Jiantao Hu, fuming Xu, Liyue Huang, Mi Wang, Shaomeng Wang

Cancer Res (2021) 81 (13_Supplement): 1231.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1231

Published: 01 July 2021

View article

Journal Articles

Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities

Cancer Res (2021) 81 (13_Supplement): 2123.

DOI: https://doi.org/10.1158/1538-7445.AM2021-2123

Published: 01 July 2021

View article

Journal Articles

Abstract 73: Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor

Jianyong Chen, Chengzhe Wu, Lingling Jiao, Leilei Zhao, Yunlong Zhou, Dongbo Li, Guozhi Tang, Shoulai Gu, Jing Deng, Guangfeng Wang, Douglas D. Fang, Shaomeng Wang, Dajun Yang, Yifan Zhai

Cancer Res (2020) 80 (16_Supplement): 73.

DOI: https://doi.org/10.1158/1538-7445.AM2020-73

Published: 15 August 2020

View article

Journal Articles

Abstract 1960: Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Xin Han, Lijie Zhao, Weiguo Xiang, Chong Qin, Bukeyan Miao, Tianfeng Xu, Jianfeng Lu, Mi Wang, Shaomeng Wang

Cancer Res (2020) 80 (16_Supplement): 1960.

DOI: https://doi.org/10.1158/1538-7445.AM2020-1960

Published: 15 August 2020

View article

Journal Articles

Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Steven Kregel, Chao Wang, Xin Han, Lanbo Xiao, Ester Fernandez-Salas, Pushpinder Bawa, Brooke L. McCollum, Kari Wilder-Romans, Ingrid J. Apel, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan

Cancer Res (2020) 80 (16_Supplement): 5679.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5679

Published: 15 August 2020

View article

Journal Articles

Abstract 1036: Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED)

Changwei Wang, Rohan Kalyan Rej, Jianfeng Lu, Mi Wang, Kaitlin P. Harvey, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey, Elyse Petrunak, Caroline Foster, Yunlong Zhou, Rubin Zhou, Guozhi Tang, Jianyong Chen, Shaomeng Wang

Cancer Res (2020) 80 (16_Supplement): 1036.

DOI: https://doi.org/10.1158/1538-7445.AM2020-1036

Published: 15 August 2020

View article

Journal Articles

BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1

Dan Zong, Jiajia Gu, Giovanna C. Cavalcante, Weilong Yao, Guojing Zhang, Shaomeng Wang, Taofeek K. Owonikoko, Xia He, Shi-Yong Sun

Cancer Res (2020) 80 (11): 2380–2393.

DOI: https://doi.org/10.1158/0008-5472.CAN-19-3674

Published: 02 June 2020

View article

Includes: Supplementary data

Journal Articles

Abstract 1001: Functional and mechanistic interrogation of androgen receptor degraders for the treatment of metastatic castration resistant prostate cancer

Steven Kregel, Chao Wang, Ester Fernandez-Salas, Kari Wilder-Romans, Xin Han, Chong Qin, Weiguo Xiang, Jean Tien, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan

Cancer Res (2019) 79 (13_Supplement): 1001.

DOI: https://doi.org/10.1158/1538-7445.AM2019-1001

Published: 01 July 2019

View article

Journal Articles

Abstract 1754: Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models

Wentao Pan, Douglas D. Fang, Guangfeng Wang, Miaoyi Wu, Yingfeng Li, Keji Lian, Dingxiong Cheng, Yanhui Kong, Guoqin Zhai, Ming Guo, Shaomeng Wang, Dajun Yang, Yifan Zhai

Cancer Res (2018) 78 (13_Supplement): 1754.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1754

Published: 01 July 2018

View article

Journal Articles

Abstract 5795: Functional and mechanistic interrogation of BET Bromodomain degraders for the treatment of metastatic castration resistant prostate cancer

Steven Kregel, Rohit Malik, Irfan A. Asangani, Ester Fernandez-Salas, Kari Wilder-Romans, Xia Jiang, Thekkelnaycke Rajendiran, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan

Cancer Res (2018) 78 (13_Supplement): 5795.

DOI: https://doi.org/10.1158/1538-7445.AM2018-5795

Published: 01 July 2018

View article

Journal Articles

Abstract 307: Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models

GuangFeng Wang, Ping Min, MiaoYi Wu, Shuo Dang, ChuanYan Tang, Fei Zhang, Ming Guo, Shaomeng Wang, Jing Deng, Douglas D. Fang, DaJun Yang, YiFan Zhai

Cancer Res (2018) 78 (13_Supplement): 307.

DOI: https://doi.org/10.1158/1538-7445.AM2018-307

Published: 01 July 2018

View article

Journal Articles

Abstract 5083: A novel and highly efficacious small-molecule degrader of BET-BRD proteins for the treatment of acute leukemia

Ester Fernandez-Salas, Zhuo Chen, Mei Lin, Bing Zhou, Donna McEachern, Sally Przybranowski, Karson Kump, Luke F. Peterson, Malathi Kandarpa, Jiantao Hu, Fuming Xu, Liu Liu, Longchuan Bai, Bo Wen, Duxin Sun, Moshe Talpaz, Shaomeng Wang

Cancer Res (2017) 77 (13_Supplement): 5083.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5083

Published: 01 July 2017

View article

Journal Articles

Abstract 5074: Therapeutic targeting of bromodomain and extra-terminal proteins degradation in triple-negative breast cancer

Longchuan Bai, Bing Zhou, Chao-Yie Yang, Jiao Ji, Donna McEachern, Sally Przybranowski, Shaomeng Wang

Cancer Res (2017) 77 (13_Supplement): 5074.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5074

Published: 01 July 2017

View article

Journal Articles

Abstract 2: Functional and mechanistic interrogation of BET bromodomain degraders for the treatment of metastatic castration resistant prostate cancer

Steven Kregel, Rohit Malik, Irfan A. Asangani, Kari Wilder-Romans, Xia Jiang, Ingrid J. Apel, Gautham Ravi, Jean Tien, Xuhong Cao, Felix Y. Feng, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan

Cancer Res (2017) 77 (13_Supplement): 2.

DOI: https://doi.org/10.1158/1538-7445.AM2017-2

Published: 01 July 2017

View article

Journal Articles

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Cancer Res (2017) 77 (9): 2476–2487.

DOI: https://doi.org/10.1158/0008-5472.CAN-16-2622

Published: 30 April 2017

View article

Includes: Supplementary data

Journal Articles

Abstract 1250: Antitumor activities of CD161, a structurally novel and orally bioavailable BET inhibitor, in leukemia and triple negative breast cancer cells in vitro and in vivo

Longchuan Bai, Yujun Zhao, Liu Liu, Chao-Yie Yang, Donna McEachern, Jeanne Stuckey, Jennifer Meagher, Bo Wen, Duxin Sun, Shaomeng Wang

Cancer Res (2016) 76 (14_Supplement): 1250.

DOI: https://doi.org/10.1158/1538-7445.AM2016-1250

Published: 15 July 2016

View article

Journal Articles

Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma

Casey G. Langdon, Norbert Wiedemann, Matthew A. Held, James T. Platt, Ramanaiah Mamillapalli, Pinar Iyidogan, Nicholas Theodosakis, Frederic Levy, Denis Robichon, Claudio Zanna, Gregoire Vuagniaux, Mel Sorensen, Shaomeng Wang, Marcus W. Bosenberg, David F. Stern

Cancer Res (2015) 75 (15_Supplement): 2529.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2529

Published: 01 August 2015

View article

2 3 4

NARROW

Abstract 3939: Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy

Abstract 2664: Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors

Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer

Abstract 1231: Identification of selective Brd4 degrader for cancer treatment

Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities

Abstract 73: Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor

Abstract 1960: Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Abstract 1036: Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED)

BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1

Abstract 1001: Functional and mechanistic interrogation of androgen receptor degraders for the treatment of metastatic castration resistant prostate cancer

Abstract 1754: Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models

Abstract 5795: Functional and mechanistic interrogation of BET Bromodomain degraders for the treatment of metastatic castration resistant prostate cancer

Abstract 307: Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models

Abstract 5083: A novel and highly efficacious small-molecule degrader of BET-BRD proteins for the treatment of acute leukemia

Abstract 5074: Therapeutic targeting of bromodomain and extra-terminal proteins degradation in triple-negative breast cancer

Abstract 2: Functional and mechanistic interrogation of BET bromodomain degraders for the treatment of metastatic castration resistant prostate cancer

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Abstract 1250: Antitumor activities of CD161, a structurally novel and orally bioavailable BET inhibitor, in leukemia and triple negative breast cancer cells in vitro and in vivo

Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only